Symphony Health to provide free access to new MetysTM COVID-19 Module for U.S. based life sciences industry during pandemic
April 08 2020 - 4:05PM
PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony
Health, a PRA Health Sciences company, will make a 30-day license
of its newly released MetysTM COVID-19 Module available to the U.S.
life science industry at no charge.
The COVID-19 Module within the Metys platform will provide up to
three users per company with access to all drugs and markets within
any U.S. geographic region down to CBSA (core-based statistical
area). The module will include history back to October 2018 to
ensure access to comparative flu season trends in prior years, with
March 2020 data becoming available on April 10. Companies may
publish or report insights or findings from the data with prior
permission from Symphony.
Powered by Symphony’s IDV® (Integrated Dataverse), Metys is the
first platform of its kind that delivers pharmaceutical market
analytics and intelligence that is both timely and comprehensive.
Metys is a web-based tool that intelligently integrates
prescription, payer, and anonymized patient data through one single
access point — all while delivering insights faster than any other
tool in the industry. Metys accesses over 60 terabytes of
automatically included weekly and monthly data, reflecting the
breadth of data and advancements in machine learning.
“COVID-19 has delivered an unprecedented challenge to the life
sciences industry here in the U.S. and beyond,” said Doug Fulling,
President, Symphony Health. “As we mobilize to fight COVID-19,
those in life sciences can use the data and insights available to
see trends, to react quickly and then plan for the future. We are
hoping this level of insight from one of the most robust databases
in the U.S. market benefits not only our clients and their
patients, but also society as a whole.”
Life science organizations that would like to activate this
offer can contact Symphony Health at solutions@symphonyhealth.com
or by filling out the form:
https://symphonyhealth.prahs.com/covid-19.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is one of the
world’s leading global contract research organizations by revenue,
providing outsourced clinical development and data solution
services to the biotechnology and pharmaceutical industries. PRA’s
global clinical development platform includes more than 75 offices
across North America, Europe, Asia, Latin America, South Africa,
Australia and the Middle East and more than 17,500 employees
worldwide. Since 2000, PRA has participated in approximately 4,000
clinical trials worldwide. In addition, PRA has participated in the
pivotal or supportive trials that led to U.S. Food and Drug
Administration or international regulatory approval of more than 95
drugs. For more information, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES: Laurie Hurst, Director, Communications and
Public RelationsHurstLaurie@prahs.com, +1.919.786.8435
ABOUT SYMPHONY HEALTH
A wholly-owned subsidiary of PRA
Health Sciences, Symphony Health is a leading provider of
high-value data, analytics, and technology solutions for
biopharmaceutical manufacturers, healthcare providers, and payers.
The company helps clients understand disease incidence, prevalence,
progression, treatment, and influences along the patient and
prescriber journeys by connecting and integrating a broad set of
primary and secondary data, and providing health research,
analytics, and consulting expertise. Symphony
Health derived data improves health management decisions, and
helps clients drive revenue growth while providing critical
insights on how to effectively adapt to the changing healthcare
ecosystem. For more information about Symphony Health, please visit
www.symphonyhealth.prahs.com.
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Sep 2024 to Oct 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Oct 2023 to Oct 2024